and approval before being made available to the public.
If it is successful, R78C could become part of the new generation of malaria vaccines, paving the way to disease control and eradication.
Exam-Focused Points
- Oxford and Serum Institute enter deal to create R78C malaria vaccine.
- Aims to stop Plasmodium falciparum , the most deadly malaria parasite.
- Multi- stage (blood-stage antigens RIPR and CyPRA).
- Not like R21/Matrix-M, which targets sporozoite.
- SII allows cost-effective vaccine manufacturing.
- R78C is in clinical trials .
- Malaria can be prevented through vaccines, mosquito control and treatment.
Month: Current Affairs - April 29, 2026
Category: Health and Biotechnology